Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics
(NQ:
CLDX
)
26.22
-0.18 (-0.68%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celldex Therapeutics
< Previous
1
2
3
4
5
6
Next >
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
September 26, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
September 25, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
4 Analysts Have This to Say About Celldex Therapeutics
May 31, 2023
Via
Benzinga
Celldex Therapeutics: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Why Celldex Therapeutics Shares Are Trading Higher Today
February 27, 2023
Via
Benzinga
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
December 19, 2022
Via
Benzinga
Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27
August 27, 2023
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
August 22, 2023
Via
Benzinga
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 11, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
July 06, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
June 10, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
June 08, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
May 31, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
May 15, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRT) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
May 11, 2023
Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2023
Via
Benzinga
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 29, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
February 27, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
February 26, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
February 16, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
February 15, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
February 03, 2023
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
These '20 Stocks To Watch' Moved On Last Fed Rate Hike: How Will They React Today?
February 01, 2023
The Federal Reserve's interest rate hike announcements have the potential to cause significant volatility in the stock market.
Via
Benzinga
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 14, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Topics
Death
Exposures
Death
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 14, 2022
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing...
Via
TheNewswire.com
Topics
Death
Exposures
Death
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.